Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 794930, 9 pages
http://dx.doi.org/10.1155/2014/794930
Review Article

Evaluating the Cancer Therapeutic Potential of Cardiac Glycosides

1Department of Pharmacology, Faculty of Pharmacy, University of Seville, 41012 Seville, Spain
2Department of Cell Biology, Faculty of Biology, University of Seville, Spain

Received 27 February 2014; Revised 25 April 2014; Accepted 28 April 2014; Published 8 May 2014

Academic Editor: Gautam Sethi

Copyright © 2014 José Manuel Calderón-Montaño et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. H. Rahimtoola and T. Tak, “The use of digitalis in heart failure,” Current Problems in Cardiology, vol. 21, no. 12, pp. 781–853, 1996. View at Google Scholar
  2. Z. Xie and A. Askari, “Na+/K+-ATPase as a signal transducer,” European Journal of Biochemistry, vol. 269, no. 10, pp. 2434–2439, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. W. Schoner and G. Scheiner-Bobis, “Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth,” American Journal of Physiology-Cell Physiology, vol. 293, no. 2, pp. C509–C536, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Haux, “Digitoxin is a potential anticancer agent for several types of cancer,” Medical Hypotheses, vol. 53, no. 6, pp. 543–548, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. M. López-Lázaro, “Digitoxin as an anticancer agent with selectivity for cancer cells: possible mechanisms involved,” Expert Opinion on Therapeutic Targets, vol. 11, no. 8, pp. 1043–1053, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. R. A. Newman, P. Yang, A. D. Pawlus, and K. I. Block, “Cardiac glycosides as novel cancer therapeutic agents,” Molecular Interventions, vol. 8, no. 1, pp. 36–49, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. I. Prassas and E. P. Diamandis, “Novel therapeutic applications of cardiac glycosides,” Nature Reviews Drug Discovery, vol. 7, no. 11, pp. 926–935, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Mijatovic, E. Van Quaquebeke, B. Delest, O. Debeir, F. Darro, and R. Kiss, “Cardiotonic steroids on the road to anti-cancer therapy,” Biochimica et Biophysica Acta-Reviews on Cancer, vol. 1776, no. 1, pp. 32–57, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Mijatovic, F. Dufrasne, and R. Kiss, “Cardiotonic steroids-mediated targeting of the Na+/K+-ATPase to combat chemoresistant cancers,” Current Medicinal Chemistry, vol. 19, no. 5, pp. 627–646, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Mijatovic and R. Kiss, “Cardiotonic steroids-mediated Na+/K+-ATPase targeting could circumvent various chemoresistance pathways,” Planta Medica, vol. 79, no. 3-4, pp. 189–198, 2013. View at Publisher · View at Google Scholar
  11. M. Slingerland, C. Cerella, H. J. Guchelaar, M. Diederich, and H. Gelderblom, “Cardiac glycosides in cancer therapy: from preclinical investigations towards clinical trials,” Invest New Drugs, vol. 31, no. 4, pp. 1087–1094, 2013. View at Google Scholar
  12. P. Babula, M. Masarik, V. Adam, I. Provaznik, and R. Kizek, “From Na+/K+-ATPase and cardiac glycosides to cytotoxicity and cancer treatment,” Anti-Cancer Agents in Medicinal Chemistry, vol. 13, no. 7, pp. 1069–1087, 2013. View at Google Scholar
  13. C. Cerella, M. Dicato, and M. Diederich, “Assembling the puzzle of anti-cancer mechanisms triggered by cardiac glycosides,” Mitochondrion, vol. 13, no. 3, pp. 225–234, 2013. View at Google Scholar
  14. Y. Sreenivasan, P. B. Raghavendra, and S. K. Manna, “Oleandrin-mediated expression of Fas potentiates apoptosis in tumor cells,” Journal of Clinical Immunology, vol. 26, no. 4, pp. 308–322, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Hallböök, J. Felth, A. Eriksson et al., “Ex vivo activity of cardiac glycosides in acute leukaemia,” PLoS ONE, vol. 6, no. 1, Article ID e15718, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. M. López-Lázaro, N. Pastor, S. S. Azrak, M. J. Ayuso, C. A. Austin, and F. Cortés, “Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients,” Journal of Natural Products, vol. 68, no. 11, pp. 1642–1645, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Zhang, D. Z. Qian, Y. S. Tan et al., “Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 50, pp. 19579–19586, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Tailler, L. Senovilla, E. Lainey et al., “Antineoplastic activity of ouabain and pyrithione zinc in acute myeloid leukemia,” Oncogene, vol. 31, no. 30, pp. 3536–3546, 2012. View at Google Scholar
  19. Y. Wang, D. M. Lonard, Y. Yu et al., “Bufalin is a potent small molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1,” Cancer Research, vol. 74, no. 5, pp. 1506–1517, 2014. View at Google Scholar
  20. L. J. Rashan, K. Franke, M. M. Khine et al., “Characterization of the anticancer properties of monoglycosidic cardenolides isolated from Nerium oleander and Streptocaulon tomentosum,” Journal of Ethnopharmacology, vol. 134, no. 3, pp. 781–788, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. J. M. Calderon-Montano, E. Burgos-Moron, M. L. Orta, S. Mateos, and M. Lopez-Lazaro, “A hydroalcoholic extract from the leaves of Nerium oleander inhibits glycolysis and induces selective killing of lung cancer cells,” Planta Medica, vol. 79, no. 12, pp. 1017–1023, 2013. View at Publisher · View at Google Scholar
  22. A. Perne, M. K. Muellner, M. Steinrueck et al., “Cardiac glycosides induce cell death in human cells by inhibiting general protein synthesis,” PloS ONE, vol. 4, no. 12, Article ID e8292, 2009. View at Google Scholar · View at Scopus
  23. R. J. Clifford and J. H. Kaplan, “Human breast tumor cells are more resistant to cardiac glycoside toxicity than non-tumorigenic breast cells,” PLoS ONE, vol. 8, no. 12, Article ID e84306, 2013. View at Google Scholar
  24. J. M. Calderon-Montano, E. Burgos-Moron, and M. Lopez-Lazaro, “The in vivo antitumor activity of cardiac glycosides in mice xenografted with human cancer cells is probably an experimental artifact,” Oncogene, 2013. View at Publisher · View at Google Scholar
  25. M. Lopez-Lazaro, “Digoxin, HIF-1, and cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 9, p. E26, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. J. M. Calderon-Montano, E. Burgos-Moron, and M. Lopez-Lazaro, “Comment on “Quiescence and gammaH2AX in neuroblastoma are regulated by Ouabain/Na, K-ATPase”: ouabain and cancer,” British Journal of Cancer, vol. 108, no. 10, pp. 2189–2190, 2013. View at Google Scholar
  27. H. Hiyoshi, S. Abdelhady, L. Segerstrom et al., “Quiescence and gammaH2AX in neuroblastoma are regulated by ouabain/Na, K-ATPase,” British Journal of Cancer, vol. 106, no. 11, pp. 1807–1815, 2012. View at Google Scholar
  28. D. M. Zhang, J. S. Liu, L. J. Deng et al., “Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway,” Carcinogenesis, vol. 34, no. 6, pp. 1331–1342, 2013. View at Google Scholar
  29. R. S. Gupta, A. Chopra, and D. K. Stetsko, “Cellular basis for the species differences in sensitivity to cardiac glycosides (digitalis),” Journal of Cellular Physiology, vol. 127, no. 2, pp. 197–206, 1986. View at Google Scholar · View at Scopus
  30. T. Mijatovic, I. Roland, E. Van Quaquebeke et al., “The α1 subunit of the sodium pump could represent a novel target to combat non-small cell lung cancers,” Journal of Pathology, vol. 212, no. 2, pp. 170–179, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. P. Yang, D. G. Menter, C. Cartwright et al., “Oleandrin-mediated inhibition of human tumor cell proliferation: importance of Na,K-ATPase α subunits as drug targets,” Molecular Cancer Therapeutics, vol. 8, no. 8, pp. 2319–2328, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. P. Yang, C. Cartwright, E. Efuet et al., “Cellular location and expression of Na+, K+ -ATPase alpha subunits affect the anti-proliferative activity of oleandrin,” Mol Carcinog, 2012. View at Google Scholar
  33. A. Svensson, F. Azarbayjani, U. Bäckman, T. Matsumoto, and R. Christofferson, “Digoxin inhibits neuroblastoma tumor growth in mice,” Anticancer Research, vol. 25, no. 1, pp. 207–212, 2005. View at Google Scholar · View at Scopus
  34. R. B. Zavareh, K. S. Lau, R. Hurren et al., “Inhibition of the sodium/potassium ATPase impairs N-glycan expression and function,” Cancer Research, vol. 68, no. 16, pp. 6688–6697, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. C. C. Wong, H. Zhang, D. M. Gilkes et al., “Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis,” Journal of Molecular Medicine, vol. 90, no. 7, pp. 803–815, 2012. View at Google Scholar
  36. H. Zhang, C. C. L. Wong, H. Wei et al., “HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs,” Oncogene, vol. 31, no. 14, pp. 1757–1770, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. L. Schito, S. Rey, M. Tafani et al., “Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 40, pp. E2707–E2716, 2012. View at Google Scholar
  38. B. A. Gayed, K. J. O. 'Malley, J. Pilch, and Z. Wang, “Digoxin inhibits blood vessel density and HIF-1a expression in castration-resistant C4-2 xenograft prostate tumors,” Clinical and Translational Science, vol. 5, no. 1, pp. 39–42, 2012. View at Google Scholar
  39. C. Antczak, C. Kloepping, C. Radu et al., “Revisiting old drugs as novel agents for retinoblastoma: in vitro and in vivo antitumor activity of cardenolides,” Investigative Ophthalmology and Visual Science, vol. 50, no. 7, pp. 3065–3073, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. C. D. Simpson, I. A. Mawji, K. Anyiwe et al., “Inhibition of the sodium potassium adenosine triphosphatase pump sensitizes cancer cells to anoikis and prevents distant tumor formation,” Cancer Research, vol. 69, no. 7, pp. 2739–2747, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. T. Mijatovic, A. O. De Beeck, E. Van Quaquebeke et al., “The cardenolide UNBS1450 is able to deactivate nuclear factor κB-mediated cytoprotective effects in human non-small cell lung cancer cells,” Molecular Cancer Therapeutics, vol. 5, no. 2, pp. 391–399, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. T. Mijatovic, V. Mathieu, J. Gaussin et al., “Cardenolide-induced lysosomal membrane permeabilization demonstrates therapeutic benefits in experimental human non-small cell lung cancers,” Neoplasia, vol. 8, no. 5, pp. 402–412, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. T. Mijatovic, N. De Nève, P. Gailly et al., “Nucleolus and c-Myc: potential targets of cardenolide-mediated antitumor activity,” Molecular Cancer Therapeutics, vol. 7, no. 5, pp. 1285–1296, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. F. Lefranc, T. Mijatovic, Y. Kondo et al., “Targeting the α1 subunit of the sodium pump to combat glioblastoma cells,” Neurosurgery, vol. 62, no. 1, pp. 211–221, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. V. Mathieu, C. Pirker, E. Martin de Lassalle et al., “The sodium pump α1 sub-unit: a disease progression-related target for metastatic melanoma treatment,” Journal of Cellular and Molecular Medicine, vol. 13, no. 9, pp. 3960–3972, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. Z. J. Lu, Y. Zhou, Q. Song et al., “Periplocin inhibits growth of lung cancer in vitro and in vivo by blocking AKT/ERK signaling pathways,” Cellular Physiology and Biochemistry, vol. 26, no. 4-5, pp. 609–618, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. C. F. Cheng, I. H. Lu, H. W. Tseng et al., “Antitumor effect of periplocin in TRAIL-resistant human hepatocellular carcinoma cells through downregulation of IAPs,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 958025, 11 pages, 2013. View at Publisher · View at Google Scholar
  48. C. E. Badr, T. Wurdinger, J. Nilsson et al., “Lanatoside C sensitizes glioblastoma cells to tumor necrosis factor-related apoptosisinducing ligand and induces an alternative cell death pathway,” Neuro-Oncology, vol. 13, no. 11, pp. 1213–1224, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. Y. Chen, Q. Guo, B. Zhang, M. Kang, Q. Xie, and Y. Wu, “Bufalin enhances the antitumor effect of gemcitabine in pancreatic cancer,” Oncology Letters, vol. 4, no. 4, pp. 792–798, 2012. View at Google Scholar
  50. X. B. Xie, J. Q. Yin, L. L. Wen et al., “Critical role of heat shock protein 27 in bufalin-induced apoptosis in human osteosarcomas: a proteomic-based research,” PLoS ONE, vol. 7, no. 10, Article ID e47375, 2012. View at Google Scholar
  51. D. M. Zhang, J. S. Liu, M. K. Tang et al., “Bufotalin from Venenum Bufonis inhibits growth of multidrug resistant HepG2 cells through G2/M cell cycle arrest and apoptosis,” European Journal of Pharmacology, vol. 692, no. 1–3, pp. 19–28, 2012. View at Google Scholar
  52. N. Han, J. Yang, L. Li et al., “Inhibitory activity of a phytochemically characterized fraction from streptocaulon juventas on lung cancer in nude mice,” Planta Medica, vol. 76, no. 6, pp. 561–565, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. N. Takai, T. Ueda, M. Nishida, K. Nasu, and H. Narahara, “Bufalin induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells,” International Journal of Molecular Medicine, vol. 21, no. 5, pp. 637–643, 2008. View at Google Scholar · View at Scopus
  54. Y. B. Moreno, E. Urban, M. Gelbcke et al., “Structure-activity relationship analysis of bufadienolide-induced in vitro growth inhibitory effects on mouse and human cancer cells,” Journal of Natural Products, vol. 76, no. 6, pp. 1078–1084, 2013. View at Google Scholar
  55. H. A. Elbaz, T. A. Stueckle, H. L. Wang et al., “Digitoxin and a synthetic monosaccharide analog inhibit cell viability in lung cancer cells,” Toxicology and Applied Pharmacology, vol. 258, no. 1, pp. 51–60, 2012. View at Publisher · View at Google Scholar · View at Scopus